CSL Limited (ASX:CSL)
175.93
-1.06 (-0.60%)
Nov 5, 2025, 2:57 PM AEST
CSL Limited Revenue
In the fiscal year ending June 30, 2025, CSL Limited had annual revenue of $15.56B USD with 5.12% growth. CSL Limited had revenue of $7.08B in the half year ending June 30, 2025, with 15.49% growth.
Revenue
$15.56B
Revenue Growth
+5.12%
P/S Ratio
3.60
Revenue / Employee
$520.26K
Employees
29,904
Market Cap
85.55B AUD
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 15.56B | 758.00M | 5.12% |
| Jun 30, 2024 | 14.80B | 1.49B | 11.19% |
| Jun 30, 2023 | 13.31B | 2.75B | 26.02% |
| Jun 30, 2022 | 10.56B | 252.00M | 2.44% |
| Jun 30, 2021 | 10.31B | 1.16B | 12.67% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ramsay Health Care | 17.79B |
| Sonic Healthcare | 9.65B |
| Ansell | 3.06B |
| Cochlear | 2.34B |
| Regis Healthcare | 1.16B |
| Telix Pharmaceuticals | 1.01B |
| Neuren Pharmaceuticals | 218.86M |
| Pro Medicus | 212.98M |
CSL Limited News
- 7 days ago - CSL Limited (CSLLY) Shareholder/Analyst Call Transcript - Seeking Alpha
- 8 days ago - CSL Limited (CSLLY) Shareholder/Analyst Call - Slideshow - Seeking Alpha
- 9 days ago - CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE) - PRNewsWire
- 14 days ago - Recent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatric and Adult Populations Relative to Standard Egg-Based Influenza Vaccines - PRNewsWire
- 4 weeks ago - My Top 5 Biotech Stocks Big Pharma Could Buy Next - Seeking Alpha
- 4 weeks ago - CSL Behring Canada Signs LOI With PCPA For Public Reimbursement Of HEMGENIX - Nasdaq
- 2 months ago - CSL Limited falls as layoffs overshadow FY25 results - Seeking Alpha
- 2 months ago - CSL Limited (CSLLY) Q4 2025 Earnings Call Transcript - Seeking Alpha